ClinicalTrials.gg
RecruitingNCT05878860LIGHTHOUSEUpdated Sep 29, 2026

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

A Phase 3 interventional study of ATSN-201 in X-linked Retinoschisis, sponsored by Atsena Therapeutics Inc.. Recruiting at 21 sites in 3 countries. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Atsena Therapeutics Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Sep 29, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinoschisis with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Retinoschisis · United States.

Started
2023
the only one that year
Phase 3
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Atsena Therapeutics Inc.

Among the 10 studies in Retinoschisis with a site in United States, this one is the only one that started in 2023, is the only one in phase 3, and was the 9th registered.

Retinoschisis

19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.

Browse Retinoschisis studies →

Open to participants now

3 of the 10 studies in Retinoschisis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Retinoschisis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinoschisis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS).

Read the detailed description

The study is designed in three parts: a dose escalation phase (Part A), a dose expansion phase (Part B) and a randomized, controlled phase (Part C).

In Part C of the study, eligible patients who enroll in this study will be randomly assigned to be treated with ATSN-201 or to have no treatment; subjects assigned to ATSN-201 will receive the drug as a one-time subretinal injection of ATSN-201 in one eye or both eyes, depending on whether only one or both eyes meet criteria for treatment. Subjects will have regular assessments for 1 year as part of the Main Study Period and additional assessments over the next 4 years as part of the Extension Study Period.

Some subjects may have all their study visits at a surgery site.

Some subjects may go to one study site (a medical site) to determine eligibility and another study site (a surgery site) to have surgery - including pre-operative care and approximately 1-week of post-operative care per treated eye. After the surgery, they will go back to the other study site (the medical site) to complete the follow-up visits.

Subjects who do not receive treatment as part of the control group can choose to receive ATSN-201 in one or both eyes after the 1-year Main Study Period if eligible. If the subject is not eligible at the Month 12 visit, eligibility may be reassessed at the Month 18 visit.

03

Conditions studied

  • X-linked Retinoschisis

Browse trials for

Keywords

  • XLRS, RS1
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part A and B:

Inclusion Criteria:

  1. Age ≥ 18 for Cohorts 1 through 4, and age ≥ 6 years and \< 18 years for Cohort 5.
  2. Male patients with clinical diagnosis of XLRS caused by mutations in RS1.
  3. Best corrected visual acuity (BCVA) in study eye of 34 to 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (corresponding to a Snellen acuity of 20/200 to 20/40).
  4. Presence of foveal schisis and /or parafoveal/perifoveal schisis in the study eye on SD-OCT per the Principal Investigator.

Exclusion Criteria:

  1. Pre-existing eye conditions in the study eye that would contribute significantly to an increased risk of visual loss from a subretinal injection (eg, advanced glaucoma, optic neuropathy, uveitis, corneal transplants).
  2. Any intraocular surgery (including laser treatment) in the study eye within 6 months prior to Screening or any intraocular surgery anticipated in the study eye during the first 12 months of the study.
  3. Treatment in a prior ocular gene or cell therapy study.

Part C:

Inclusion Criteria:

Note: For patients ineligible for bilateral dosing based on the ocular exclusion criteria, the same eye must meet all ocular inclusion criteria, but none of the ocular exclusion criteria, to be eligible for unilateral dosing.

General All of the following criteria must be met for unilateral or bilateral dosing.

  1. Age ≥ 5 years.
  2. Genetically male patients with clinical diagnosis of XLRS caused by pathogenic or likely pathogenic mutations in RS1 OR Genetically female patients with clinical diagnosis of XLRS caused by biallelic pathogenic or likely pathogenic mutations in RS1.

    Ocular At least 1 eye must meet all of the following criteria for both unilateral and bilateral dosing.

  3. BCVA of 34 to 73 ETDRS letters (corresponding to a Snellen acuity of 20/200 to 20/40).
  4. Presence of foveal schisis on SD-OCT.

Exclusion Criteria:

General None of the following criteria can be met for unilateral or bilateral dosing.

  1. Treatment with any carbonic anhydrase inhibitor (oral or topical) within 1 month prior to Screening.
  2. Treatment in a prior ocular gene or cell therapy study.
  3. Absence of macular schisis.
  4. BCVA better than 75 ETDRS letters (corresponding to a Snellen acuity of 20/32).
  5. Pre-existing eye conditions that would contribute significantly to an increased risk of visual loss from a subretinal injection (eg, advanced glaucoma, optic neuropathy, uveitis, corneal transplants).
  6. Any intraocular surgery (including laser treatment) within 6 months prior to Screening or any intraocular surgery anticipated during the first 12 months of the study (laser treatment is allowed as long as it occurs at least 2 weeks before surgery).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
97 participants (estimated)

Study arms

  • Experimental
    Cohort 1, Low Dose

    Biological: ATSN-201

  • Experimental
    Cohort 2, High Dose

    Biological: ATSN-201

  • Experimental
    Cohort 3, Mid Dose

    Biological: ATSN-201

  • Experimental
    Cohort 4, Low Volume

    Biological: ATSN-201

  • Experimental
    Cohort 4, High Volume

    Biological: ATSN-201

  • No intervention
    Cohort 4, Control
  • Experimental
    Cohort 5, Pediatric

    Biological: ATSN-201

  • Experimental
    Cohort 6, Treatment

    Biological: ATSN-201

  • No intervention
    Cohort 6, Control

Interventions

  • BiologicalATSN-201

    AAV.SPR-hGRK1-hRS1syn

06

What researchers measure

Primary outcomes

  1. Part A (Dose Escalation) and Part B (Dose Expansion): Safety and tolerability as assessed by dose-limiting toxicities and treatment-emergent adverse events

    Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs).

    Time frame: From baseline to week 52

  2. Part C (Phase 3, Randomized, Controlled) Effect of ATSN-201 on visual function.

    Proportion of subjects with improvement ≥ 7dB from baseline in microperimetry across prespecified loci in the study eye.

    Time frame: From baseline to week 52

Secondary outcomes

  1. Part A and Part B: Visual acuity as assessed by best-corrected visual acuity

    Change in best-corrected visual acuity (BCVA).

    Time frame: From baseline to week 52

  2. Part A and Part B: Visual acuity as assessed by low-luminance visual acuity

    Change in low-luminance visual acuity (LLVA).

    Time frame: From baseline to week 52

  3. Part A and Part B: Visual function as assessed by contrast sensitivity

    Change in contrast sensitivity.

    Time frame: From baseline to week 52

  4. Part A and Part B: Visual function as assessed by microperimetry

    Change in microperimetry.

    Time frame: From baseline to week 52

  5. Part A and Part B: Macular structure as assessed by spectral domain optical coherence tomography

    Change in spectral domain optical coherence tomography (SD-OCT).

    Time frame: From baseline to week 52

  6. Part A and Part B: Macular structure as assessed by fundus autofluorescence

    Change in fundus autofluorescence (FAF).

    Time frame: From baseline to week 52

  7. Part A and Part B: Subject-reported visual function as assessed by the NEI VFQ-25 in adult subjects

    Change in the National Eye Institute's Visual Function Questionnaire 25 (NEI VFQ-25) score for adult subjects with scores from 0 to 100 where a higher score indicates a better outcome.

    Time frame: From baseline to week 52

  8. Part A and Part B: Subject-reported visual function as assessed by the CVAQC in pediatric subjects

    Change in the Cardiff Visual Ability Questionnaire for Children (CVAQC) score for pediatric subjects with scores from -3.00 to +2.80 where a higher score indicates a worse outcome.

    Time frame: From baseline to week 52

  9. Part A and Part B: Subject-reported visual function as assessed by the MRDQ in subjects 13 years of age or greater.

    Description: Change in the Michigan Retinal Degeneration Questionnaire (MRDQ) score for subjects 13 years of age or greater.

    Time frame: From baseline to week 52

  10. Part C: Macular structure as assessed by spectral domain optical coherence tomography

    Change in spectral domain optical coherence tomography (SD-OCT).

    Time frame: From baseline to week 52

  11. Part C: Visual acuity as assessed by best-corrected visual acuity or low-luminance visual acuity

    Change in best-corrected visual acuity (BCVA) or low luminance visual acuity (LLVA).

    Time frame: From baseline to week 52

  12. Part C: Visual acuity as assessed by best-corrected visual acuity as measured by Early Treatment Diabetic Retinopathy Study chart

    Change in best-corrected visual acuity (BCVA) as assessed by ETDRS.

    Time frame: From baseline to week 52

  13. Part C: Visual acuity as assessed by low luminance visual acuity as measured by Early Treatment Diabetic Retinopathy Study chart

    Description: Change in low luminance visual acuity (LLVA) as assessed by ETDRS.

    Time frame: From baseline to week 52

  14. Part C: Visual function as assessed by microperimetry

    Change in microperimetry for subjects.

    Time frame: From baseline to week 52

  15. Part C: Functional vision as assessed by reading speed

    Change from baseline in reading speed as measured by MNREAD for subjects 8 years of age and older.

    Time frame: From baseline to week 52

  16. Part C: Subject-reported visual function as assessed by the MRDQ in subjects 13 years of age or greater

    Change in the Michigan Retinal Degeneration Questionnaire (MRDQ) score for subjects 13 years of age or greater.

    Time frame: From baseline to week 52

  17. Part C: Subject-reported visual function as assessed by the CVAQC in pediatric subjects

    Change in the Cardiff Visual Ability Questionnaire for Children (CVAQC) score for pediatric subjects ages 5-13 years of age.

    Time frame: From baseline to week 52

  18. Part C: Subject perception of change and severity (PGIC/PGIS)

    Patient global impression of change and severity (PGIC/PGIS).

    Time frame: From baseline to week 52

  19. Part C: Evaluate the safety of ATSN-201

    Incidence of treatment emergent adverse events (TEAEs).

    Time frame: From baseline to week 52

  20. Part C: To evaluate the quality of life in subjects treated with ATSN-201

    Change from Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Health Index score and Visual Analogue Scale (VAS) score at Month 12 for subjects ≥ 12 years of age in the ATSN-201 group vs. controls. Scale 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: From baseline to week 52

  21. Part C: To evaluate the quality of life in pediatric patients treated with ATSN-201

    Change from Baseline in European Quality of Life 5-Dimension Youth 5-Level (EQ-5D-Y-5L) Health Index score and Visual analogue Scale (VAS) score at Month 12 for subjects ≥ 8 to \< 12 years of age in the ATSN201 group vs. controls. Scale 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: From baseline to week 52

07

Study locations

15 of 21 sites recruiting
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
    Recruiting
    • Benjamin Bakall, MD · Principal investigator
  • Shiley Eye Institute
    La Jolla, California 92093, United States
    Not yet recruiting
    • Shyamanga Borooah, MD · Principal investigator
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
    • Aaron Nagiel, MD, PhD · Principal investigator
  • Stanford University
    Palo Alto, California 94303, United States
    Not yet recruiting
    • Vinit Mahajan, MD · Principal investigator
  • UC San Francisco
    San Francisco, California 94158, United States
    Recruiting
    • Jacque Duncan, MD · Principal investigator
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
    Recruiting
    • Byron Lam, MD · Principal investigator
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02114, United States
    Recruiting
    • Rachel Huckfeldt, MD · Principal investigator
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Anne Fulton, MD · Principal investigator
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Thomas Wubben, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Raymond Iezzi, MD · Principal investigator
  • Columbia University
    New York, New York 100032, United States
    Recruiting
    • Aliaa Abdelhakim, MD · Principal investigator
  • Flaum Eye Institute, University of Rochester
    Rochester, New York 14642, United States
    Not yet recruiting
    • Alex Levin, MD · Principal investigator
  • Duke University
    Durham, North Carolina 27710, United States
    Recruiting
    • Lejla Vajzovic, MD · Principal investigator
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
    Recruiting
    • Lesley Everett, MD, PhD, MPhil · Principal investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Tomas Aleman, MD · Principal investigator
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Recruiting
    • Mark Pennesi, MD · Principal investigator
  • Moran Eye Center
    Salt Lake City, Utah 84132, United States
    Recruiting
    • Eileen Hwang, MD · Principal investigator
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
    Recruiting
    • Melanie Schmitt, MD · Principal investigator
  • The Hospital for Sick Children
    Toronto, Ontario M5G 0A4, Canada
    Not yet recruiting
    • Elise Heon, MD · Principal investigator
  • McGill University (MUHC)
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
    • Robert Koenekoop, MD · Principal investigator
  • Oxford Eye Hospital
    Oxford, England OX3 9DU, United Kingdom
    Recruiting
    • Dominik Fischer, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Apr 2028, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
May 26, 2023
StartActual
Aug 22, 2023
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2033
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University of Wisconsin · Madison, United StatesNot yet recruiting→Recruiting
  • Oxford Eye Hospital · Oxford, United KingdomNot yet recruiting→Recruiting
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of Wisconsin · Madison, United StatesNot yet recruiting→Recruiting
    • Oxford Eye Hospital · Oxford, United KingdomNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05878860
Lead sponsor
Atsena Therapeutics Inc.
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Aug 22, 2023
Primary completion
Apr 2028 (estimated)
Completion
Apr 2033 (estimated)
Last update
Sep 29, 2026

Study contacts

Atsena Therapeutics Clinical Trials
Contact
clinicaltrials@atsenatx.com
984-261-2001

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion